Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes.

Journal of virology - 1 Oct 2009

Quercia Romina, Dam Elisabeth, Perez-Bercoff Danielle, Clavel François

Abstract excerpt

The emergence of human immunodeficiency virus type 1 resistance to raltegravir, an integrase strand transfer inhibitor, follows distinct and independent genetic pathways, among which the N155H and Q148HKR pathways are the most frequently encountered in treated patients. After prolonged viral escape, mutants of the N155H pathway are replaced by mutants of the Q148HKR pathway. We have examined the mechanisms...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dose-Response Relationship, Drug
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genome, Viral

Share to HIV Integrase

Share to HIV Integrase Inhibitors

Share to Inhibitory Concentration 50

Share to Pyrrolidinones

Share to Raltegravir Potassium

Source

Open in PubMed Open full text

Identifiers

PMID: 19605484
DOI: 10.1128/JVI.00894-09
PMCID: PMC2747997

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes.PMID 19605484Read ↗

Temporal Evolution of Drug Resistance to HIV Integrase Inhibitors.Semantic proximity Read ↗

An evolutionary-based approach to quantify the genetic barrier to drug resistance in fast-evolving viruses: an application to HIV-1 subtypes and integrase inhibitorsSemantic proximity Read ↗

Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase InhibitorsSemantic proximity Read ↗

Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of DrugSemantic proximity Read ↗

Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.Semantic proximity Read ↗

Comprehensive mapping of the virus and host factors that guide the paths of HIV-1 escape from a therapeutic.Semantic proximity Read ↗

Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.Semantic proximity Read ↗

Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.Semantic proximity Read ↗

Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistanceSemantic proximity Read ↗

Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.Semantic proximity Read ↗

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.Semantic proximity Read ↗

Evolution of HIV integrase resistance mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.